Structural heart disease refers to the pathophysiological changes of the heart caused by anatomical abnormalities changes in the heart structure, including congenital heart disease, valvular disease, and others. Valvular heart disease is characterized by damage to or defects in one or more of the four heart valves, namely, aortic valve, mitral valve, tricuspid valve, and pulmonary valve. Normal and functioning valves ensure proper blood flow, but valvular heart diseases cause the valves to become too narrow and hardened to open fully, stenosis or unable to close completely (regurgitation).
Three major approaches for treatment of valvular heart disease include medication, surgery, and interventional therapy. Medication mainly aims to alleviate the patients' symptoms by prescribing varied medicines in accordance with certain patients' symptoms. Surgery mainly aims to fundamentally rectify the structural defects of the heart valves.
Currently, interventional therapy is advancing rapidly and is considered as a safe and minimal invasive treatment suitable for elderly patients with high surgical risks, poor health and other complications. With technology development, indications for interventional therapy are broadening. Unlike conventional surgeries which usually cause large surgical incision in order to treat diseased vessels, resulting in higher risks of operative infection and complications, slower recovery rate and larger dose of anesthesia, interventional therapy provides less invasive treatment with fewer post-operative complication, faster recovery period and shorter hospital stay.
NewMed is a high-end medical device company dedicated to the R&D and production of transcatheter valvular devices, with complete independent research and development, testing and production capabilities. The company's product line covers the aortic valve, mitral valve, tricuspid valve and pulmonary valve, and provides domestic leading comprehensive and innovative solutions for heart valve intervention. Three of our product candidates were recognized by the NMPA as innovative medical devices qualified for Special Review.
Applying our strong in-house R&D capabilities, We have built up a sizable patent portfolio to protect our wide-ranging proprietary technologies. Our extensive, yet close-knit expert and institution networks have helped us, and will continue to help us, stay ahead of technological progress and up-to-date on latest developments in technology. we are hopeful and optimistic about bringing innovative products to market, and improving the lives of countless patients with structural heart disease.